Dupixent 300 MG/2 ML pen 2ML
Ended Awarded Last action
- Contract number
- SPE2DR26FL0ZQ
- Awardee
-
Amerisourcebergen Drug Corp UEI KABZK8W6PQT3 Part of Cencora, Inc.
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $93,009
Award facts
- Contract value 100% obligated
- $93,009.17 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Conshohocken, PA 19428, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a $93,009.17 firm fixed-price delivery order to AmerisourceBergen Drug Corp for DUPIXENT (dupilumab) 300 mg/2 ml pen injectables, with an ultimate completion date of January 13, 2026. This non-set-aside contract represents a task order under AmerisourceBergen's parent company Cencora, Inc.'s larger Indefinite Delivery Contract with DLA Troop Support Medical, valued at up to $999,999,999.00 through December 2031. The parent IDC serves as a comprehensive global pharmaceutical support vehicle enabling the delivery of a broad range of pharmaceutical products and medical supplies to support military healthcare programs worldwide, including specialty medications, brand-name and generic drugs, vaccines, and medical devices across multiple therapeutic domains.
AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor and critical vendor for federal medical procurement needs serving military and veteran healthcare systems. The company's contract performance demonstrates extensive experience fulfilling federal pharmaceutical supply requirements through open competition, with delivery orders typically structured on firm fixed-price terms. This delivery order for DUPIXENT—a biologic immunosuppressant used primarily to treat atopic dermatitis, eczema, and other inflammatory conditions—supports the Defense Health Agency and other federal healthcare systems' ongoing pharmaceutical procurement requirements.
Quick answers
Who was awarded contract SPE2DR26FL0ZQ?
SPE2DR26FL0ZQ was awarded to Amerisourcebergen Drug Corp by Defense Logistics Agency (Department of Defense) on January 12, 2026.
How much is contract SPE2DR26FL0ZQ worth?
The government has obligated $93,009 on SPE2DR26FL0ZQ.
Is contract SPE2DR26FL0ZQ an order under another contract?
Yes. SPE2DR26FL0ZQ is a delivery order under SPE2DR25D3401, an indefinite delivery contract.
Was contract SPE2DR26FL0ZQ competed?
The extent of competition for SPE2DR26FL0ZQ was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award